FibroGen Q3 2023 Adj EPS $(0.52) Beats $(0.68) Estimate, Sales $40.13M Beat $36.84M Estimate
Portfolio Pulse from saritha@benzinga.com
FibroGen (NASDAQ:FGEN) reported Q3 2023 earnings with losses of $(0.52) per share, beating the analyst consensus estimate of $(0.68) by 23.53%. This is a 46.94% increase over losses from the same period last year. The company also reported quarterly sales of $40.13 million, beating the analyst consensus estimate of $36.84 million by 8.94%, a 155.06% increase over sales from the same period last year.
November 06, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FibroGen reported better than expected Q3 2023 earnings and sales, indicating a positive financial performance.
FibroGen's Q3 2023 earnings beat analyst estimates, with losses per share lower than expected and sales higher than expected. This indicates a strong financial performance, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100